UK retail sales growth ‘minimal’ in final quarter of 2024, data shows

Pinterest (NYSE: PINS) experienced a 12% stock drop following its second-quarter earnings report, despite stronger-than-expected revenue growth; however, lower profitability and concerns over new tariffs impacting ad demand contributed to investor apprehension. This situation raises questions for long-term investors about whether it presents a buying opportunity or if it’s prudent to wait. Want More Context? 🔎

Artificial intelligence (AI) is expected to significantly boost the global economy, potentially contributing nearly $20 trillion to GDP by the decade's end, prompting substantial investment in AI stocks like Nvidia, Broadcom, Palantir, and Snowflake. For those who missed earlier gains, Meta Platforms and Lam Research present attractive investment opportunities as they leverage the AI surge while trading at appealing multiples. Want More Context? 🔎

To qualify as a growth stock, a company must be expected to grow significantly faster than the overall market, which narrows down the options considerably. Despite the challenge of identifying these stocks, the author suggests three promising growth stocks to invest in right now with $1,000, emphasizing their potential for substantial market outperformance. Want More Context? 🔎

In this podcast, Motley Fool contributors Travis Hoium, Lou Whiteman, and Rachel Warren explore the potential impact of the NFL on Disney's stock performance. They also encourage listeners to access full episodes of their podcasts and consider their top 10 stock recommendations when ready to invest. Want More Context? 🔎

Retiring solely on Social Security is not advisable as benefits typically replace less than half of a worker's income, making it challenging for seniors to adjust to reduced earnings. Despite this, many seniors depend exclusively on Social Security due to difficulties in saving for retirement, heavily relying on annual cost-of-living adjustments (COLAs) for financial stability. Want More Context? 🔎

Vertex Pharmaceuticals (NASDAQ: VRTX) reported its second-quarter results, leading to a more than 17% drop in shares during early trading on Tuesday, despite the results not being poor overall. The negative investor reaction stemmed from two disappointing developments in its pipeline, which may present buying opportunities for some investors. Want More Context? 🔎